From the CUPIC study: Great times are not coming (?)

Journal of Hepatology

Volumn 60, Issue 4, 2014, Pages 899-900

  Schmidt Martin, Daniel ^a   Houlihan, Diarmaid ^a   McCormick, Aidan ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; OLIGOPEPTIDE; PROLINE;

ANTIVIRAL THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DEATH; DECOMPENSATED LIVER CIRRHOSIS; HEPATITIS C; HISTORY; HOSPITAL ADMISSION; HUMAN; HYPOALBUMINEMIA; LETTER; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; MORTALITY; OUTCOME ASSESSMENT; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; FEMALE; HEPATITIS C, CHRONIC; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; OLIGOPEPTIDES; PROLINE;

EID: 84896393959     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.11.035     Document Type: Letter

References (11)

1. C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, and V. Canva et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic)-nct01514890 J Hepatol 59 2013 434 441
2. B.L. Pearlman, and N. Traub Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more Clin Infect Dis 52 2011 889 900
3. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
4. A. Craxì EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
5. A. Iacobellis, M. Siciliano, F. Perri, B.E. Annicchiarico, G. Leandro, and N. Caruso et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study J Hepatol 46 2007 206 212
6. G.T. Everson, N.A. Terrault, A.S. Lok, D.R. Rodrigo, R.S. Brown, and S. Saab et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation Hepatology 57 2013 1752 1762
7. I. Rowe, D. Houlihan, and D. Mutimer Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit Aliment Pharmacol Ther 36 2012 670 679
8. C.W.H. Moreno, and I. Fenandez et al. Efficacy and safety results of treatment of patients over 65 years old with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis: the International Telaprevir Early Access Program Hepatology 58 2013 1130A 1131A
9. P.R. Abrao Ferreira, M. Colombo, and P. Urbanek et al. Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: efficacy results to week 16 on 1587 patients from the International Telaprevir Early Access Program Hepatology 58 2013 1108A 1109A
10. A.A. Qamar, N.D. Grace, R.J. Groszmann, G. Garcia-Tsao, J. Bosch, and A.K. Burroughs et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis Clin Gastroenterol Hepatol 7 2009 689 695
11. R.P. Myers, A.A.M. Shaheen, P. Faris, A.I. Aspinall, and K.W. Burak Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list PLoS One 8 2013 e51926